Practice Apoptosis: When Partners Retire

Article

Kicking off the first in a series of podcasts, a noted healthcare consultant discusses how retirement can fracture a practice.

In today’s challenging environment, community oncology practices must devise new business models if they are to continue providing high quality care for patients while adequately compensating their physicians. Practices must also adapt to an environment in which professional-fee revenue plays an increasingly important role in reimbursing for care.

In short, busy community doctors need to create a sound business plan that complements the skills and needs of their partners. Building the right practice “chemistry” is tantamount to success. So, what happens when a partner, or two, decides to retire? In this podcast, noted healthcare consultant, Thomas A. Paivanas, discusses the realities, with the caveat, fortune favors a prepared mind.

Stay tuned for our next expert podcast: Martin Neltner talks about quality in cancer care, what it means to the busy practitioner as we move forward into our brave new world of healthcare…
 

           
 

Practice Apoptosis: When Partners Retire
Right mouse click and "Save As" to download

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content